Cite
HARVARD Citation
Miller, C. et al. (2022). Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab. Frontline gastroenterology. 13 (5), pp. 392-401. [Online].